ORIGINAL ARTICLETargeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Key Words
Cited by (0)
Disclosure: B. Besse received grants from GSK and Roche; A. Curioni received consulting fees from Roche and Boehringer-Ingelheim; J. Diebold received consulting fees from Pfizer and Roche; M. Früh received consulting fee from Roche; D. Koeberle received consulting fees From Merck and Lilly; S. Michels received: consulting fees from Novartis, Pfizer, and Boehringer-Ingelheim; G. Pall received travel grant and consulting fees from Roche and GSK; S. Rothschild received consulting fees from Lilly, BMS, Roche and Pfizer; M. Scheffler received consulting fees from BMS, Novartis, and Boehringer-Ingelheim; M. Schuler received consulting fees from AstraZeneca, Boehringer-Ingelheim, Celgene, Novartis, and Lilly and research grants from Boehringer Ingelheim and Novartis; R. Veillon received travel grant and consulting fees from Roche and Boehringer-Ingelheim; J. Wolf received consulting fees from AstraZeneca and Boehringer-Ingelheim; G. Zalcman received consulting fee from GSK. All other authors declared no conflicts of interest. The study was academic and not supported by industry.
This study was presented as a proffered paper at the International Association for the Study of Lung Cancer-European Society of Medical Oncology European Lung Cancer Conference on April 17, 2015 in Geneva.